2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.115 (Poster) Real-World Characteristics and Outcomes Among Patients With Advanced Non-Small Cell Lung Cancer and HER2 Mutations

Pdf Summary

This study presented at the North America Conference on Lung Cancer (NACLC) 2023 Annual Meeting aimed to describe the real-world clinical characteristics, treatment patterns, and outcomes of patients with HER2 mutation-positive advanced non-small cell lung cancer (NSCLC). The study used a noninterventional/observational cohort design and collected data from the deidentified Flatiron Health (FH)-Foundation Medicine, Inc. (FMI) Clinico-Genomic Database (CGDB), which contains real-world clinical data from approximately 280 cancer centers in the United States.<br /><br />The study included adults with a histologically or cytologically confirmed diagnosis of advanced or metastatic NSCLC between January 1, 2015, and March 31, 2021. The analysis was conducted in three cohorts: HER2 mutation cohort, 1L HER2 mutation cohort (first-line treatment), and 2L HER2 mutation cohort (second-line treatment). The patients' clinical characteristics, treatment patterns, and outcomes were analyzed.<br /><br />The results showed that 4.7% of the patients had a HER2 mutation. Patients with a HER2 mutation in the tyrosine kinase domain (TKD) tended to be female, never-smokers, and had lower tumor mutational burden (TMB) compared to patients with a non-TKD HER2 mutation. The most commonly used treatment in the first-line setting was platinum-based chemotherapy, either alone or with immunotherapy. In the second-line setting, immune checkpoint inhibitors (IO) with or without chemotherapy were most commonly used.<br /><br />The study also reported real-world overall survival (rwOS) and real-world progression-free survival (rwPFS) in both the first-line and second-line settings. The results suggested a trend towards better clinical outcomes with pembrolizumab-based triplet therapy in the first-line setting.<br /><br />The study acknowledged some limitations, such as the reliance on data from the FH-FMI CGDB, which may not include all patients, and the evolving therapeutic landscape for patients with HER2 mutation-positive NSCLC.<br /><br />In conclusion, this large US-based real-world study provided further insight into the epidemiology, treatment patterns, and outcomes of patients with HER2 mutation-positive NSCLC. The findings highlighted the potential differences in tumor biology between TKD and non-TKD HER2 mutations and emphasized the importance of pembrolizumab-based triplet therapy in the first-line setting.

Asset Subtitle

Christina Baik

Keywords

North America Conference on Lung Cancer

HER2 mutation-positive NSCLC

real-world clinical characteristics

treatment patterns

outcomes

TKD HER2 mutation

pembrolizumab-based triplet therapy

rwOS

rwPFS

epidemiology